← FDA DRUG APPROVALS

FDA ANDA · ANDA206879

NEVIRAPINE

Sponsor: MACLEODS PHARMS LTD

APPLICATION
ANDA206879
TYPE
ANDA
ORIGINAL APPROVAL
2017-10-06
LATEST ACTION
2023-06-07
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

NEVIRAPINEPrescription
NEVIRAPINE 400MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2023-06-07Labeling · Supplement 15 · standardAP
2019-08-14Labeling · Supplement 6 · standardAP
2017-10-06UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →